Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
You must be a Standard 1 Year member to access this content.
Goodwin advised BrainStorm on the offering, and Ellenoff Grossman advised the placement agent. BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced its registered direct offering of 4,054,055...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised GreenLight Biosciences, Foley Hoag advised the Special Committee, while O’Melveny & Myers advised Fall Line on the deal. GreenLight Biosciences Holdings, PBC (NASDAQ:...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Fulcrum Therapeutics on the deal. Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced its underwritten public offering of 9,615,384 shares of its common stock at...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ventyx Biosciences on the deal while Goodwin Procter represented Redmile Group. Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company focused on...
You must be a Standard 1 Year member to access this content.
